Contributor Disclosures for Thrombasthenia
Role Name Disclosure Details
Author Noah Federman, MD, Department of Pediatrics, Fellow, Division of Pediatric Hematology/Oncology, Mattel Children's Hospital at UCLA, David Geffen School of Medicine at U Nothing to discloseDetails
Coauthor Kathleen Sakamoto, MD, Professor, Department of Pediatrics, Mattel Children's Hospital, David Geffen School of Medicine, Division of Hematology-Oncology and Pathology and Laboratory Medicine, University of California at Los Angeles Nothing to discloseDetails
Coauthor Mark E Green, MD, Chief, Department of Emergency Medicine, Emergency Medicine, Gateway Medical System Nothing to discloseDetails
Coauthor Lawrence S Frankel, MD, Director of Pediatric Hematology/Oncology, Scott and White Clinic; Professor, Department of Pediatrics, Division of Hematology/Oncology, Texas A&M University School of Medicine Nothing to discloseDetails
Medical Editor J Martin Johnston, MD, Associate Professor of Pediatrics, Mercer University School of Medicine; Director of Pediatric Hematology/Oncology, Backus Children's Hospital; Consulting Oncologist/Hematologist, St Damien's Pediatric Hospital Nothing to discloseDetails
Pharmacy Editor Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc
Avanir Pharma
Details
Managing Editor James L Harper, MD, Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Assistant Clinical Professor, Department of Pediatrics, Creighton University; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center Nothing to discloseDetails
CME Editor Helen SL Chan, MBBS, FRCP(C), FAAP, Senior Scientist, Research Institute; Professor, Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada Nothing to discloseDetails
Chief Editor Robert J Arceci, MD, PhD, King Fahd Professor of Pediatric Oncology, Department of Oncology, Division of Pediatric Oncology, Johns Hopkins University School of Medicine Nothing to discloseDetails









Contributor:
Contributor Disclosure:
Noah Federman, Author  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Kathleen Sakamoto

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication









Contributor Disclosure


Contributor:
Contributor Disclosure:
Mark E Green, Coauthor  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Lawrence S Frankel, Coauthor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
J Martin Johnston

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Mary L Windle

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Pfizer Inc
StockInvestment from broker recommendation 
Avanir Pharma
StockInvestment from broker recommendation 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
James L Harper

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Helen Sl Chan

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Robert J Arceci

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication